Is Harmony Biosciences Holdings, Inc. (HRMY) a Buy, Sell, or Hold?
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$34.81 USD
-$0.73 (-2.05%)
- Volume
- 938.75K
- Average Volume
- 819.33K
- Market Capitalization
- $2.02B
- P/E Ratio
- 13.81
- Dividend Yield
- 0.00%
- Price Target
- $46.00
- Year High
- $40.87
- Year Low
- $25.52
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.58
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jeffrey Dayno |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | HRMY |
| CUSIP | 413197104 |
| CIK | 0001802665 |
| Web | https://www.harmonybiosciences.com |
| Phone | 484 539 9800 |
| Currency | USD |
| Employees | 293 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.23 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.58 |
| Quick Ratio | 3.56 |
| Cash Ratio | 2.71 |
Sales & Book Value
| Annual Sales | $868.45M |
| Price / Sales | 2.24 |
| Cash Flow | 5.91 |
| Price / Cash Flow | 5.90 |
| Price / Book | 2.21 |
Price Target and Rating
| Average Stock Price Forecast | $46.00 |
| High Stock Price Forecast | $50.00 |
| Low Stock Price Forecast | $36.00 |
| Forecast Upside/Downside | -24.33% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.71 |
| Trailing P/E Ratio | 13.81 |
| PEG Ratio | -2.31 |
| P/E Growth | -2.31 |
| Net Income | $158.69M |
| Net Margin | 16.20% |
| Pretax Margin | 21.97% |
| Return on Equity | 17.19% |
| Return on Assets | 11.45% |
Financials Score
| AltmanZ Score | 5.43 |
| Piotroski Score | 5.00 |
| Working Capital | 561.48M |
| Total Assets | 1.27B |
| Ebit | 208M |
| Market Cap | 2.07B |
| Total Liabilities | 361.48M |
Poll Results
About Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania. ...
HRMY vs. AMGN: Which Stock Is the Better Value Option?
2026-07-14 12:40:26
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns
2026-07-14 11:31:06
Five low price-to-book stocks pass our value screens with low P/B, P/S and PEG metrics, highlighting their earnings growth potential.
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
2026-07-14 10:40:22
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for July 14th
2026-07-14 07:56:05
MEOH, LTM and HRMY made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 14th, 2026.
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?
2026-06-29 14:46:07
Harmony Biosciences trades at discounted valuations, but investors are weighing Wakix dependence, recent earnings misses and pipeline execution.
Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline
2026-06-29 14:41:10
Harmony Biosciences is leveraging Wakix growth to expand its neuroscience pipeline, while advancing pitolisant programs and rare disease assets.
HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase
2026-06-29 14:41:07
Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to diversify growth.
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
2026-06-11 09:00:00
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster pr
Frequently Asked Questions
-
What is the current Harmony Biosciences Holdings, Inc. (HRMY) stock price?
-
Harmony Biosciences Holdings, Inc.(NASDAQ:HRMY) stock price is $34.81 in the last trading session. During the trading session, HRMY stock reached the peak price of $40.87 while $25.52 was the lowest point it dropped to. The percentage change in HRMY stock occurred in the recent session was --2.05% while the dollar amount for the price change in HRMY stock was -$-0.73.
-
HRMY's industry and sector of operation?
-
The NASDAQ listed HRMY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HRMY?
-
Tricia Glover | Chief Compliance Officer
Brennan Doyle | Vice President & Head of Investor Relations
Jeffrey Dayno | President, Chief Executive Officer & Director
Christian Ulrich | Executive VP, General Counsel & Corporate Secretary
Glenn Reicin | Chief Financial Officer -
How many employees does HRMY have?
-
Number of HRMY employees currently stands at 293. HRMY operates from 630 West Germantown Pike, Plymouth Meeting, PA 19462, US.
-
Link for HRMY official website?
-
Official Website of HRMY is: https://www.harmonybiosciences.com
-
How do I contact HRMY?
-
HRMY could be contacted at phone #484 539 9800 and can also be accessed through its website. HRMY operates from 630 West Germantown Pike, Plymouth Meeting, PA 19462, US.
-
How many shares of HRMY are traded daily?
-
The average number of HRMY shares traded daily for last 3 months was 819.33K.
-
What is the market cap of HRMY currently?
-
The market value of HRMY currently stands at $2.02B with its latest stock price at $34.81